FDA Declines Approval of China-Developed Lung Cancer Drug After Survival Goal Missed
The setback affects a multibillion-dollar biotech partnership as Washington increases scrutiny of clinical trial data from China. Mark Us Preferred on Google The U.S. Food and Drug Administration has declined to approve a China-developed lung cancer drug after an international clinical trial failed to establish that patients receiving the treatment…